Tag: Takeda pharmaceuticals

While several drug manufacturers received FDA approval for generic forms of MyDayis in 2022 and 2023, the brand is protected by active patents [1.2.4, 1.4.5, 1.4.8]. The answer to 'When did MyDayis go generic?' is complex; while technically available, a broad launch is tied to patent expirations.

Originally co-developed by Millennium Pharmaceuticals and Janssen, the ownership and commercialization rights of the cancer drug Velcade are now split between two major pharmaceutical players. Takeda Pharmaceuticals, which acquired Millennium in 2008, handles the United States market, while Janssen Pharmaceutical Companies of Johnson & Johnson manage sales and distribution in Europe and most other parts of the world.

First approved by the FDA in 2010, the medication known as VPRIV was originally manufactured by Shire plc. This article details the complex manufacturing history of VPRIV, explaining how it transitioned from its original developer to being produced by Takeda Pharmaceuticals today.

Takeda Pharmaceuticals is the current manufacturer of Cinryze, but the medication has a rich history involving several pharmaceutical companies. First developed by ViroPharma, the rights to Cinryze were later acquired by Shire before eventually being integrated into Takeda's portfolio following a major corporate acquisition. This complex journey reflects the consolidation common within the modern pharmaceutical industry.